MA51679A - Composés destinés au traitement de troubles dépendant de la kinase - Google Patents
Composés destinés au traitement de troubles dépendant de la kinaseInfo
- Publication number
- MA51679A MA51679A MA051679A MA51679A MA51679A MA 51679 A MA51679 A MA 51679A MA 051679 A MA051679 A MA 051679A MA 51679 A MA51679 A MA 51679A MA 51679 A MA51679 A MA 51679A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase
- treatment
- compounds intended
- dependent disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622702P | 2018-01-26 | 2018-01-26 | |
| US201862622626P | 2018-01-26 | 2018-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51679A true MA51679A (fr) | 2020-12-02 |
Family
ID=65685938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051679A MA51679A (fr) | 2018-01-26 | 2019-01-25 | Composés destinés au traitement de troubles dépendant de la kinase |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11673897B2 (fr) |
| EP (1) | EP3743417A1 (fr) |
| JP (1) | JP7480048B2 (fr) |
| CN (1) | CN111936487B (fr) |
| AU (1) | AU2019212800B2 (fr) |
| CA (1) | CA3088198A1 (fr) |
| MA (1) | MA51679A (fr) |
| WO (1) | WO2019148043A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| FI4143169T3 (fi) | 2020-04-30 | 2026-06-08 | Exelixis Inc | Kinaasi-inhibiittorin valmistusmenetelmät |
| TW202241862A (zh) * | 2021-02-01 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 二甲醯胺類化合物、其製備方法及其在醫藥上的應用 |
| MX2023009560A (es) * | 2021-02-17 | 2023-10-25 | Springworks Therapeutics Inc | Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos. |
| WO2026074526A1 (fr) * | 2024-10-04 | 2026-04-09 | Hetero Labs Limited | Composés 1,2-dicarboxamide utilisés en tant qu'inhibiteurs de kinase |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| WO2005009387A2 (fr) | 2003-07-23 | 2005-02-03 | X-Ceptor Therapeutics Inc. | Derives de l'azepine comme agents pharmaceutiques |
| EP2210607B1 (fr) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide pour le traitement du cancer |
| WO2006113546A2 (fr) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas |
| EP3530736A3 (fr) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques |
| KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용 |
| US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| WO2008076415A1 (fr) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Procédés d'utilisation d'inhibiteurs de mek |
| WO2009017838A2 (fr) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinaisons d'inhibiteurs jak-2 et d'autres agents |
| AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| CA2742007C (fr) * | 2008-10-29 | 2014-07-08 | Deciphera Pharmaceuticals, Llc | Amides de cyclopropane et analogues presentant des activites anticancereuses et antiproliferatives |
| EP2214019A1 (fr) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Marqueurs de tumeurs et leurs utilisations |
| EP2213686A1 (fr) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Marqueurs de tumeur et procédés d'utilisation correspondants |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US20130017546A1 (en) | 2009-10-26 | 2013-01-17 | Externautics S.P.A. | Breast Tumor Markers and Methods of Use Thereof |
| US10288617B2 (en) | 2009-10-26 | 2019-05-14 | Externautics Spa | Ovary tumor markers and methods of use thereof |
| US8921058B2 (en) | 2009-10-26 | 2014-12-30 | Externautics Spa | Prostate tumor markers and methods of use thereof |
| WO2011051278A1 (fr) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Marqueurs de tumeurs du poumon et leurs méthodes d'utilisation |
| WO2011051276A1 (fr) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Marqueurs de tumeurs du rectum et du côlon, et leurs méthodes d'utilisation |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| EP2383578A1 (fr) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Marqueur de tumeur et procédés d'utilisation correspondants |
| SG187064A1 (en) * | 2010-07-14 | 2013-02-28 | Zhejiang Beta Pharma Inc | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| US10359428B2 (en) | 2013-06-14 | 2019-07-23 | Externautics S.P.A. | Tumor marker, monoclonal antibodies and methods of use thereof |
| EA201690912A1 (ru) | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| JP6696908B2 (ja) * | 2014-04-25 | 2020-05-20 | エグゼリクシス， インコーポレイテッド | 肺腺癌の治療方法 |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| US20170342033A1 (en) | 2015-06-29 | 2017-11-30 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
| CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品（宁波）有限公司 | 一种防老化阳光面料 |
| CN110437145A (zh) | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| US10800741B2 (en) | 2017-02-07 | 2020-10-13 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Quinoline compound, preparation method and medical use therefor |
| WO2018153293A1 (fr) * | 2017-02-27 | 2018-08-30 | 北京赛特明强医药科技有限公司 | Dioxanoquinazoline, composé de type dioxanoquinazoline, procédé de préparation et utilisation associés |
| SG11202005719UA (en) | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| HRP20251184T1 (hr) | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| SG11202006945PA (en) | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
-
2019
- 2019-01-25 AU AU2019212800A patent/AU2019212800B2/en active Active
- 2019-01-25 CN CN201980021651.XA patent/CN111936487B/zh active Active
- 2019-01-25 EP EP19709144.0A patent/EP3743417A1/fr active Pending
- 2019-01-25 JP JP2020540745A patent/JP7480048B2/ja active Active
- 2019-01-25 WO PCT/US2019/015296 patent/WO2019148043A1/fr not_active Ceased
- 2019-01-25 CA CA3088198A patent/CA3088198A1/fr active Pending
- 2019-01-25 MA MA051679A patent/MA51679A/fr unknown
- 2019-01-25 US US16/964,274 patent/US11673897B2/en active Active
-
2023
- 2023-04-07 US US18/132,124 patent/US20240150371A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019212800B2 (en) | 2024-05-23 |
| WO2019148043A1 (fr) | 2019-08-01 |
| AU2019212800A1 (en) | 2020-08-20 |
| CA3088198A1 (fr) | 2019-08-01 |
| EP3743417A1 (fr) | 2020-12-02 |
| JP7480048B2 (ja) | 2024-05-09 |
| US20210032263A1 (en) | 2021-02-04 |
| CN111936487B (zh) | 2024-07-09 |
| JP2021511357A (ja) | 2021-05-06 |
| US11673897B2 (en) | 2023-06-13 |
| CN111936487A (zh) | 2020-11-13 |
| US20240150371A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| EP3411380A4 (fr) | Composés destinés au traitement de troubles ou de maladies oculaires | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3448389A4 (fr) | Composés de quinazoline et d'indole destinés au traitement de troubles médicaux | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3852745A4 (fr) | Composés destinés au traitement de certaines leucémies | |
| MA52778A (fr) | Méthodes de traitement de troubles associés au récepteur s1p1 | |
| EP3352749A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA56114A (fr) | Composés pour le traitement de troubles dépendant de la kinase | |
| MA52761A (fr) | Schéma posologique destiné au traitement de troubles liés à la pi3k | |
| MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
| EP3593803A4 (fr) | Composés destinés au traitement de maladies causées par l'accumulation d'oxalate | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3805216A4 (fr) | Composés pour le traitement ou la prévention de maladies hépatiques | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
| MA50356A (fr) | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 | |
| EP3877383A4 (fr) | Composés et compositions pour le traitement de maladies respiratoires | |
| EP3373931A4 (fr) | Composés hétérocycliques pour le traitement de maladies | |
| MA53636A (fr) | Agent de traitement de troubles dermatologiques | |
| EP3506927A4 (fr) | Compositions de reeline pour le traitement des troubles neurologiques | |
| MA53817A (fr) | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv | |
| MA50495A (fr) | Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires | |
| EP3630986A4 (fr) | Thérapie génique destinée au traitement de troubles des peroxysomes |